AstraZeneca PLC
camizestrant
HR-positive, HER2-negative advanced breast cancer
Resolved
35days ago
Phase 1 readout · Jun 2, 2026
What's at stake
Phase 1 trial results for camizestrant in HR-positive, HER2-negative advanced breast cancer are due Jun 2, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 6-K
verified 16h ago
“Subsequently, the Company has provided additional analyses requested by the FDA in support of the application, including ctDNA clearance data linked to longer-term efficacy outcomes that will be presented on 02 June at ASCO 2026.”